Highlight Therapeutics SL Email Format

Biotechnology ResearchSpain11-50 Employees

Highlight Therapeutics SL is a private biotechnology company in Spain focused on immuno-oncology. Its lead candidate, BO-112, is an RNA-based therapy designed to provoke a robust immune response against tumors and potentially help patients who do not respond to current checkpoint inhibitors. The approach seeks to turn cold tumors into hot tumors and is explored in both monotherapy and in combination with checkpoint inhibitors, with collaborations including Merck & Co and UCLA. The company operates as a clinical-stage biotechnology firm and was previously known as Bioncotech Therapeutics S.L. In February 2026, Mercedes Diz was appointed Chief Executive Officer to lead its strategic development.

Sign up for free to view info

Company overview Employee directory